Src inhibitors in breast cancer therapy
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recent evidence has established the non receptor tyrosine kinase, Src, as a critical component of multiple signalling pathways that regulate proliferation, survival, angiogenesis and metastasis. Increased levels of Src protein and activity are widely reported in human cancers including breast cancer, and its important role in oncogenic processes makes it a potential target for therapeutic intervention. OBJECTIVE: To review the role of Src kinase in breast cancer and discuss its potential as a therapeutic target. METHODS: Literature citing preclinical and clinical studies with Src inhibitors was reviewed. CONCLUSION: Experimental data with small-molecule inhibitors of Src kinase in breast cancer are encouraging, demonstrating effective suppression in vitro of tumour growth and invasion and inhibition of disease spread in preclinical models in vivo. Recently several Src inhibitors have been tested in Phase I clinical trials where they are well tolerated and demonstrate low toxicity. Overall, these findings suggest that Src inhibitors present a future therapeutic option in the treatment of breast cancer growth and progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA
STEHELIN, D., VARMUS, H. E., BISHOP, J. M., & VOGT, P. K. (1976) · Nature · doi:10.1038/260170a0 · Cited by 1,321 · cited 1×
“Src was the first human oncogene to be discovered [1-3] and is the prototype of a non-receptor tyrosine kinase family of which eight family members (Src, Fyn, Yes, Lyn, Lck, Hck, Blk and Fgr) are expressed in humans with a further member, Yrk, found only in chickens [4] .”
BackgroundConstitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205260 · Cited by 1,207 · cited 1×
“An emerging role for Src in breast cancer is also its ability to regulate signalling elements that can promote angiogenic responses in endothelium with Src being important for VEGF induction in breast cancer cells through interaction with FAK [85] , p38 [86] and STAT3 [86,87] .”
BackgroundSrc family kinases in tumor progression and metastasis
Summy, J. M., & Gallick, G. E. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023772912750 · Cited by 827
c-Src and cooperating partners in human cancer
Ishizawar, R., & Parsons, S. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.001 · Cited by 617 · cited 2×
“(Her2), which are frequently overexpressed in breast cancer alongside Src, as positive regulators of Src activity as Src can associate with these receptors directly via its SH2 domain resulting in its activation [25-28] .”
BackgroundActivating SRC mutation in a subset of advanced human colon cancers
Irby, R. B., Mao, W., Coppola, D., Kang, J., Loubeau, J. M., Trudeau, W., Karl, R., Fujita, D. J., Jove, R., & Yeatman, T. J. (1999) · Nature Genetics · doi:10.1038/5971 · Cited by 489 · cited 1×
“In breast cancer tissue, elevated Src activity is frequently reported relative to normal breast tissue [17-19] ; this probably arises from deregulated Src protein expression and/or regulation [7] rather than genetic activation, since mutations in Src in cancer are rarely reported [20-23] .”
BackgroundHuang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T. W., Lee, F., Shaw, P., & Clark, E. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3633 · Cited by 344 · cited 1×
“Dasatinib has been shown to exert antiproliferative activity in MDA-MB-231 breast tumour cells in vitro [99] and, significantly, breast cancer cell lines representative of more aggressive disease subtypes including triple negative (oestrogen receptor-, progesterone receptor-, Her2-) breast disease appear to have incre…”
BackgroundMaa, M. C., Leu, T. H., McCarley, D. J., Schatzman, R. C., & Parsons, S. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.6981 · Cited by 330 · cited 1×
“Indeed, Src and the EGFR have been shown to synergise, enhancing neoplastic growth of mammary epithelial cells [7,39] ; consequently, inhibition of Src activity can prevent EGFRmediated proliferation [40,41] .”
BackgroundZheng, X., Resnick, R. J., & Shalloway, D. (2008) · International Journal of Cancer · doi:10.1002/ijc.23321 · Cited by 60 · cited 1×
“Oestrogen-receptor-alpha-negative primary breast cancers and cell lines show increased Src levels and/or activity compared with oestrogen-receptor-alpha-positive cancers and cells [65] whilst small interfering RNA (siRNA)mediated suppression of Src expression or the Src-regulatory phosphatise, PTP α , induces apoptoso…”
Backgroundc-Src-Mediated Epithelial Cell Migration and Invasion Regulated by PDZ Binding Site
Baumgartner, M., Radziwill, G., Lorger, M., Weiss, A., & Moelling, K. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01024-07 · Cited by 28
Cited by
The extracellular matrix in breast cancer
Insua-Rodríguez, J., & Oskarsson, T. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.017 · Cited by 470
Src family kinases and paclitaxel sensitivity
Le, X.-F., & Bast, Jr. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.4.16430 · Cited by 79
Chen, P.-H., Peng, C.-Y., Pai, H.-C., Teng, C.-M., Chen, C.-C., & Yang, C.-R. (2011) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2010.06.004 · Cited by 28
“In the case of breast cancer, increased Src activity is believed to play an important role in development and progression [4,5].”
BackgroundInfluential
Metadata
- Authors
- Hiscox, S., & Nicholson, R. I.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2008-05-15
- Volume
- 12
- Issue
- 6
- Pages
- 757-767
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2154534312
- Cited by
- 37
- References
- 9
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Src inhibitors in breast cancer therapy. https://app.cochat.ai/papers/10.1517/14728222.12.6.757
- The paper
- Hiscox, S., & Nicholson, R. I. (2008). Src inhibitors in breast cancer therapy. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.12.6.757
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.